Quantgene is actively engaged in multiple clinical trials and research studies to understand and validate the application of our technology to the full range of challenges in medicine.
We have partnered with some of the leading clinical institutions throughout the United States and Europe, with many more in the pipeline.
One of the largest studies in cFDNA and multi-cancer detection.
Interim results show >90% sensitivity and specificity for select stage I & II cancers.
Large target size will allow validation of multi-cancer screening capabilities.
Quantgene is exploring establishing a registry of all study participants.
Quantgene is actively engaged in research to explore the application of our technology to the full continuum of cancer as well as diseases beyond cancer.
We are interested in expanding our network of research partners, including research proposals and possible partial funding considerations. Contact us to learn more about our clinical trials.
We are researching the full course of disease in cancer including early detection, minimal residual disease, recurrence detection and tissue typing.
We are joining with clinical oncology partners to establish our technology for use in high-risk patient screening.
We are planning research for patient disease profiling and reversibility in a range of diseases.